Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4750940
Max Phase: Preclinical
Molecular Formula: C132H233N51O29S3
Molecular Weight: 3094.84
Molecule Type: Unknown
Associated Items:
ID: ALA4750940
Max Phase: Preclinical
Molecular Formula: C132H233N51O29S3
Molecular Weight: 3094.84
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](N)CCCCNC(=O)CCCCC(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CC(C)C)NC1=O
Standard InChI: InChI=1S/C132H233N51O29S3/c1-14-74(6)102-121(208)177-90(60-73(4)5)116(203)180-92(69-214-215-70-93(119(206)182-102)179-106(193)79(133)27-17-18-44-152-96(186)36-15-16-37-97(187)153-53-54-210-55-56-211-57-58-212-68-101(191)181-104(132(11,12)13)122(209)183-67-78(184)61-94(183)120(207)164-63-76-38-40-77(41-39-76)103-75(7)166-71-213-103)118(205)174-87(35-26-52-161-130(150)151)114(201)178-91(62-131(8,9)10)117(204)176-89(59-72(2)3)115(202)175-88(42-43-95(134)185)107(194)165-65-99(189)162-64-98(188)163-66-100(190)167-81(29-20-46-155-124(138)139)108(195)169-83(31-22-48-157-126(142)143)110(197)171-85(33-24-50-159-128(146)147)112(199)173-86(34-25-51-160-129(148)149)113(200)172-84(32-23-49-158-127(144)145)111(198)170-82(30-21-47-156-125(140)141)109(196)168-80(105(135)192)28-19-45-154-123(136)137/h38-41,71-74,78-94,102,104,184H,14-37,42-70,133H2,1-13H3,(H2,134,185)(H2,135,192)(H,152,186)(H,153,187)(H,162,189)(H,163,188)(H,164,207)(H,165,194)(H,167,190)(H,168,196)(H,169,195)(H,170,198)(H,171,197)(H,172,200)(H,173,199)(H,174,205)(H,175,202)(H,176,204)(H,177,208)(H,178,201)(H,179,193)(H,180,203)(H,181,191)(H,182,206)(H4,136,137,154)(H4,138,139,155)(H4,140,141,156)(H4,142,143,157)(H4,144,145,158)(H4,146,147,159)(H4,148,149,160)(H4,150,151,161)/t74-,78+,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93+,94-,102-,104+/m0/s1
Standard InChI Key: NJWUZUVRACVEED-DLQJOOFDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3094.84 | Molecular Weight (Monoisotopic): 3092.7487 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Yokoo H,Ohoka N,Naito M,Demizu Y. (2020) Design and synthesis of peptide-based chimeric molecules to induce degradation of the estrogen and androgen receptors., 28 (15): [PMID:32631565] [10.1016/j.bmc.2020.115595] |
Source(1):